Researchers uncover what drives aggressive bone cancer
A novel LTA chromothripsis mechanism is responsible for approximately 50% of high‑grade osteosarcoma cases, providing a prognostic biomarker (LOH) to predict patient outcomes
Large‑scale whole‑genome analysis of osteosarcoma patients identified a previously unrecognized LTA chromothripsis mechanism, found in roughly half of high‑grade cases. This genomic rearrangement, coupled with a loss‑of‑heterozygosity biomarker, offers a predictive tool for patient survival and highlights potential avenues for targeted therapy.
Decoding the genetic underpinnings of osteosarcoma enables clinicians to stratify patients by risk, tailor treatment plans, and potentially reduce exposure to ineffective therapeutics, thereby improving long‑term outcomes.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Systemic Therapy for Osteosarcoma and Ewing Sarcoma
- Potential proteins identified to target in osteosarcoma treatment
- Future Directions in the Treatment of Osteosarcoma
- Is There a Role for Mifamurtide in Nonmetastatic High‑Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS‑2) and Spanish Sarcoma Group (GEIS‑33) Trials
- The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights